Cost-Effectiveness Evaluation of Etoricoxib versus Celecoxib and Nonselective NSAIDs in the Treatment of Ankylosing Spondylitis in Norway

Objectives. To evaluate the cost-effectiveness of etoricoxib (90 mg) relative to celecoxib (200/400 mg), and the nonselective NSAIDs naproxen (1000 mg) and diclofenac (150 mg) in the initial treatment of ankylosing spondylitis in Norway. Methods. A previously developed Markov state-transition model...

Descripción completa

Detalles Bibliográficos
Autores principales: Jansen, Jeroen P., Taylor, Stephanie D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3134091/
https://www.ncbi.nlm.nih.gov/pubmed/21772851
http://dx.doi.org/10.1155/2011/160326

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3134091/
https://www.ncbi.nlm.nih.gov/pubmed/21772851
http://dx.doi.org/10.1155/2011/160326

Ejemplares similares